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Budget impact and cost-effectiveness analyses of the
COBRA-BPS multicomponent hypertension management
programme in rural communities in Bangladesh, Pakistan,
and Sri Lanka
Eric A Finkelstein*, Anirudh Krishnan†, Aliya Naheed†, Imtiaz Jehan†, H Asita de Silva†, Mihir Gandhi, Ching Wee Lim, Nantu Chakma,
Dileepa S Ediriweera, Jehanzeb Khan, Anuradhani Kasturiratne, Samina Hirani, A K M Solayman, Tazeen H Jafar*, COBRA-BPS study group‡

Summary

Background COBRA-BPS (Control of Blood Pressure and Risk Attenuation-Bangladesh, Pakistan, Sri Lanka), a multicomponent hypertension management programme that is led by community health workers, has been shown to be
efficacious at reducing systolic blood pressure in rural communities in Bangladesh, Pakistan, and Sri Lanka. In this
study, we aimed to assess the budget required to scale up the programme and the incremental cost-effectiveness
ratios.
Methods In a cluster-randomised trial of COBRA-BPS, individuals aged 40 years or older with hypertension who lived
in 30 rural communities in Bangladesh, Pakistan, and Sri Lanka were deemed eligible for inclusion. Costs were
quantified prospectively at baseline and during 2 years of the trial. All costs, including labour, rental, materials and
supplies, and contracted services were recorded, stratified by programme activity. Incremental costs of scaling up
COBRA-BPS to all eligible adults in areas covered by community health workers were estimated from the health
ministry (public payer) perspective.
Findings Between April 1, 2016, and Feb 28, 2017, 11 510 individuals were screened and 2645 were enrolled and
included in the study. Participants were examined between May 8, 2016, and March 31, 2019. The first-year
per-participant costs for COBRA-BPS were US$10·65 for Bangladesh, $10·25 for Pakistan, and $6·42 for Sri Lanka.
Per-capita costs were $0·63 for Bangladesh, $0·29 for Pakistan, and $1·03 for Sri Lanka. Incremental cost-effectiveness
ratios were $3430 for Bangladesh, $2270 for Pakistan, and $4080 for Sri Lanka, per cardiovascular disability-adjusted
life year averted, which showed COBRA-BPS to be cost-effective in all three countries relative to the WHO-CHOICE
threshold of three times gross domestic product per capita in each country. Using this threshold, the cost-effectiveness
acceptability curves predicted that the probability of COBRA-BPS being cost-effective is 79·3% in Bangladesh,
85·2% in Pakistan, and 99·8% in Sri Lanka.
Interpretation The low cost of scale-up and the cost-effectiveness of COBRA-BPS suggest that this programme is a
viable strategy for responding to the growing cardiovascular disease epidemic in rural communities in low-income
and middle-income countries where community health workers are present, and that it should qualify as a priority
intervention across rural settings in south Asia and in other countries with similar demographics and health systems
to those examined in this study.
Funding The UK Department of Health and Social Care, the UK Department for International Development, the
Global Challenges Research Fund, the UK Medical Research Council, Wellcome Trust.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND
4.0 license.

Introduction
Cardiovascular diseases are the leading cause of death
worldwide.1 Cardiovascular diseases are particularly
lethal in rural areas in low-income and middle-income
countries where health systems are weakest and the case
fatality rates of cardiovascular diseases are highest.2–5
Addressing this burden requires low-cost, scalable
interventions that target prevention and treatment of
hypertension, and other cardiovascular disease risk
factors.6–9

In 2020, we reported the efficacy of a clusterrandomised controlled trial, Control of Blood Pressure
and Risk Attenuation-Bangladesh, Pakistan, Sri Lanka
(COBRA-BPS), in rural communities in three southAsian countries (Bangladesh, Pakistan, and Sri Lanka).10
We showed that this contextually relevant, multicomponent intervention delivered by community health
workers (CHWs) was efficacious at reducing systolic
blood pressure.10 At 24-month follow-up, the decline
in systolic blood pressure across the three countries
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Research in context
Evidence before this study
The biomedical and health economics literature was reviewed
to identify studies in which the burden of hypertension and
cardiovascular diseases and economic evaluation of
interventions was reported, particularly from low-income and
middle-income countries. PubMed and Google Scholar
databases were searched for studies or abstracts published in
English between Jan 1, 1970, and April 20, 2020, using the
search terms “cost-effectiveness”, “blood pressure”, “lowincome countries”, “middle-income countries”, “hypertension”,
and “south Asia”. The relevant full-text articles were selected
and searched for further information and material. Although
there have been budget impact and cost-effectiveness analyses
on hypertension trials with interventions led by community
health workers in low-income and middle-income countries,
most of these trials focused on urban areas or on a single
country. The lack of evidence from rural areas in multiple
countries with differing health systems thus presents a barrier
for broad implementation.
Added value of this study
To our knowledge, this study is the first budget impact and
cost-effectiveness analysis on a scalable, community-based,

was 5·2 (95% CI 3·2–7·1) mm Hg greater in the COBRABPS cluster than in control clusters, with consistent
effects within each country.
In the present study, we report the budget impact
analysis and cost-effectiveness of a national scale-up to
rural areas within each country where CHWs are present.
The budget impact analysis allows policy makers to
budget the immediate and future costs should COBRABPS be scaled up beyond the trial communities. The
cost-effectiveness analysis facilitates the comparison of
COBRA-BPS with other interventions and helps to
establish whether the programme represents good value
for money.

Methods

Study design and participants
We did a cluster-randomised controlled trial in 30 rural
communities in Bangladesh, Pakistan, and Sri Lanka.
These 30 communities were randomly assigned to
receive either COBRA-BPS or usual care, stratified by
country (ten clusters each) and distance from the
government clinic (near [≤2 km] or far [>2 km]).
Individuals aged 40 years or older with hypertension
were eligible for inclusion in the study. The primary and
secondary outcome results of that cluster-randomised
trial were reported in 2020.10
Ethics approval for the study was obtained from the
institutional review boards of the National University of
Singapore, the Interventions Research Ethics Committee
of the London School of Hygiene & Tropical Medicine,
2

multicomponent intervention that is led by community health
workers in rural communities across three countries, namely
Bangladesh, Pakistan, and Sri Lanka. We show that, compared
with existing care, the Control of Blood Pressure and Risk
Attenuation-Bangladesh, Pakistan, Sri Lanka (COBRA-BPS)
programme is a cost-effective and scalable solution for
controlling blood pressure among individuals with
hypertension in rural areas in the three countries. The first-year
per-participant costs for scaling up COBRA-BPS were
US$10·65 for Bangladesh, $10·25 for Pakistan, and $6·42 for
Sri Lanka. Per-capita costs (total costs divided by total national
population count) were $0·63 for Bangladesh, $0·29 for
Pakistan, and $1·03 for Sri Lanka. Incremental costeffectiveness ratios were $3430 for Bangladesh, $2270 for
Pakistan, and $4080 for Sri Lanka per disability-adjusted lifeyear averted.
Implications of all the available evidence
Our findings underscore that the COBRA-BPS multicomponent
intervention presents a viable strategy to respond to the
growing cardiovascular disease epidemic in low-income and
middle-income countries and should qualify as a priority
intervention.

and institutions of each participating country (the
International Centre for Diarrhoeal Disease Research in
Bangladesh, the Aga Khan University in Pakistan, and
the University of Kelaniya in Sri Lanka).

Multicomponent intervention
COBRA-BPS was comprised of the following five
components: (1) home health education by government
CHWs, (2) blood pressure monitoring and referral,
(3) training of public and private providers in management
of hypertension, (4) designated hypertension triage
counter and care coordinators in government clinics, and
(5) a financing model to compensate for additional
services equivalent to 20% of the salary of CHWs. The
money was channelled through the district health office
and offered the flexibility to hire additional staff or expand
the role of existing staff but with the expectation that
COBRA-BPS would not compromise delivery of existing
services. Travel subsidies were allocated to low-income
participants via means testing.

Usual care
Usual care comprised of existing community services,
with CHWs routinely visiting homes for maternal and
child care only. The clinics did not have hypertensionrelated triage counters or care coordinators.

Screening, recruitment, and follow-up
Trained research staff visited all households in the study
clusters and obtained written informed consent from
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adults aged 40 years or older, who were then screened for
eligibility. Follow-up was done with home visits every
6 months for up to 2 years from baseline. Details of our
delivery approach and outcomes are available in the
study protocol and publication of results.10,11

Costs, assumptions, and budget impact analysis
We quantified all costs relating to components of
COBRA-BPS, namely: (1) administration and oversight,
(2) training of CHWs in blood pressure monitoring
and home health education, (3) training of general
practitioners, (4) implementation of home-based blood
pressure monitoring and home health education,
(5) coordination at hypertension triage counters,
(6) medical visits (including travel subsidies and costs for
additional medications), and (7) coordinating activities of
CHWs’ supervisors. Data that captured all costs of labour,
rental, materials and supplies, and contracted services
incurred by these health-care services were collected
prospectively during the trial. The cost components for
each activity are detailed in the appendix (pp 4, 5). All
costs tracking approaches and conversions are also
described in the appendix (pp 5, 6).
Both the cost-effectiveness analysis and budget impact
analysis assumed that COBRA-BPS would be scaled up
with existing CHWs, and that the programme would be
able to reach all rural households within the first year of
the scale-up. For the budget impact analysis, we estimated
the incremental cost of scaling up COBRA-BPS to all
eligible adults aged 40 years or older in areas where
CHWs are present (100% of the rural communities in
Bangladesh and Sri Lanka and 60% of the rural
communities in Pakistan) from the health ministry
(public sector) perspective. Costs for the budget impact
analysis are presented for the first 3 years of the scale-up
on the basis of recommended practices.12–14 For the costeffectiveness analysis, consistent with how decisions are
made by many countries,15 we estimated the lifetime
incremental cost from the health system perspective,
including both public and private sector costs.
Within-trial differences in health-care utilisation were
estimated as for the primary effectiveness analysis using
self-reported utilisation data captured from participants at
baseline and at 24 months. Results of the utilisation
analysis (as seen in the appendix pp 11, 12) revealed that
the only consistent (across sites) and significant difference
resulting from COBRA-BPS concerned greater use of
antihypertensive medications in the COBRA-BPS group
than the usual care group. Therefore, these costs are
included in the cost-effectiveness analysis. They are
not included in the budget impact analysis for Bangladesh
or Pakistan because the public sector does not pay for
antihypertension medications in these countries. In
Sri Lanka, COBRA-BPS data show that 63% of all clinic
visits at follow-up occurred at government facilities;
therefore, we assume that 63% of antihypertension
medication costs are paid by the government. When

forecasting future costs, we assume a medication
adherence rate of 75% that is maintained until death.16
Quantifying total costs for the budget impact analysis
requires estimating both unit costs and the number of
people expected to receive COBRA-BPS. To estimate the
number expected to receive COBRA-BPS in year 1 of
scale-up from the baseline, we multiplied estimates of
the rural population aged 40 years or older in each
country17 by estimates of hypertension prevalence
obtained during screening visits within our trial sites.
In subsequent years, cases were quantified on the basis
of an estimated hypertension incidence rate of 8·26%,
assuming an annual national population growth of
1·0% in Bangladesh, 2·0% in Pakistan, and 1·1% in
Sri Lanka.17,18 Additional details of our cost estimation
approach, including the source data and assumptions
used to generate the cost estimates, are presented in the
appendix (pp 5, 6).

Cost-effectiveness analysis
The cost-effectiveness analysis is done over a lifetime as
benefits of COBRA-BPS are expected to last indefinitely,
but the analysis is limited to the cohort of people with
hypertension identified at baseline. The numerator of the
cost-effectiveness ratio is the incremental net cost in the
first year of scale-up plus the present value of costs in
subsequent years discounted at 3% per annum.19
For the cost-effectiveness analysis, the primary measure
was prespecified as the cost per projected disabilityadjusted life-year (DALY) due to cardiovascular diseases
that have been averted. Previous literature shows a linear
association between blood pressure reduction and
percentage reduction in mortality risk due to coronary
heart disease, stroke, and cardiovascular diseases, and
reveals that a sustained reduction of 10 mm Hg in systolic
blood pressure results in a roughly 22% reduction in
coronary heart disease events and a 41% reduction in
stroke events and mortality.20 On the basis of these
statistics, we followed a model presented in previous
literature,21,22 and con
servatively assumed that every
1 mm Hg reduction in systolic blood pressure translates
into a 2·2% reduction in cardiovascular disease DALYs
and assumed that participants maintain the blood
pressure reductions throughout their lifetime.
Converting the percentage reduction in DALYs into
absolute values of cardiovascular disease DALYs requires
estimating how many cardiovascular disease DALYs
would occur in the absence of COBRA-BPS. The national
level of cardiovascular disease DALYs was obtained from
the Global Burden of Disease 2017 and adjusted by the
percentage of the population that resides in rural areas.1,17
This value was then multiplied by the percentage
reduction in cardiovascular disease DALYs conferred by
COBRA-BPS, to estimate the total cardiovascular disease
DALY reduction.
To account for uncertainty in our assumptions on the
underlying cost distribution or the exact association
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COBRA-BPS
component*
Administration and oversight

Bangladesh
(US$)†

Pakistan
(US$)†

Sri Lanka
(US$)†

1–5

$0·08

$0·49

$0·20

Training of community health workers (standardised blood pressure monitoring and home 1, 2
health education)

$4·61

$5·58

$0·33

$0·17

$0·07

Training and implementation

Training of general practitioners

3

Community health workers travel to households

1, 2

Standardised blood pressure monitoring by community health workers

2

$3·06

$2·42

$1·18

Home health education

2

$2·74

$1·52

$2·59

Coordination at hypertension triage counter

4

$0·04

$0·08

$0·03

Provision of medication subsidies

5

NA

NA

$1·75

NA

$10·65

$10·25

$6·42

First-year cost per participant

$0·12
NA

NA

$0·27‡

NA=not applicable. *The numbered COBRA-BPS components are: (1) home health education by community health workers, (2) blood pressure monitoring and stepped-up
referral to a trained general practitioner using a checklist, (3) training of public and private providers in management of hypertension and using a checklist, (4) designated
hypertension triage reception and hypertension care coordinators in government clinics, and (5) a financing model to compensate for additional health services and provide
subsidies to individuals with a low income and poorly controlled hypertension. More details can be found in the appendix (pp 5,6). †First-year costs per participant (reported
as 2020 US$) were calculated by dividing total costs for the activity in the first year by the number of eligible participants with hypertension. ‡Stipend was given as a travel
voucher for community health workers.

Table 1: First-year costs per participant by activity

between systolic blood pressure reductions and DALY
improvements, we report scenario analyses focusing on
three crucial parameters. These parameters are: (1) the
highest incremental cost per capita, (2) lowest mean
reductions of systolic blood pressure, and (3) lowest
percentage reduction in DALYs per unit reduction in
systolic blood pressure for which COBRA-BPS would
remain cost-effective in each country, based on the
common threshold of three times gross domestic product
(GDP) per capita. We then present cost-effectiveness
acceptability curves for each country, which we generated
using TreeAge Pro 2019. These curves show the
percentage of 1000 itera
tions23 that exceed a given
willingness-to-pay threshold that governments might
consider as cost-effective when costs and the association
between systolic blood pressure reductions and DALY
improvements are fixed at the base-case levels and when
the incremental improvement in systolic blood pressure
follows a normal distribution with mean and variance as
estimated in the effectiveness analysis. Results of mean
systolic blood pressure reductions are shown in the
appendix (p 13). Lastly, we explore the implications of
moving from a 3% to a 6% discount rate for costs.19
Consistent with current recommendations, DALYs are
not discounted.24

Role of the funding source
The funders of the study had no role in study design,
data collection, data analysis, data interpretation, or
writing of the report.

Results
Between April 1, 2016, and Feb 28, 2017, 11 510 individuals
were screened and 2645 were enrolled and included
in the study. Participants were examined between
4

May 8, 2016, and March 31, 2019. We estimated that
9·67 million individuals in Bangladesh, 5·62 million
individuals in Pakistan, and 3·43 million individuals
in Sri Lanka would be expected to screen positive
for hypertension (appendix p 13). On the basis of these
counts, 7·71 million (33%) of 23·47 million rural
households in Bangladesh, 3·84 million (35%) of
11·05 million rural households in Pakistan, and
2·14 million (46%) of 4·61 million rural households in
Sri Lanka would have at least one adult with hypertension
and therefore receive home health education in year 1 of
the scale-up (appendix p 13).
Table 1 presents the per-participant costs by cost
category for the budget impact analysis. Per-participant
costs were estimated to be US$10·65 for Bangladesh,
$10·25 for Pakistan, and $6·42 for Sri Lanka.
Table 2 presents the per-participant (all rural people
with hypertension aged 40 years or older) and per-capita
(of national population) costs, eligible population counts,
and total budget impact by country for the first 3 years of
implementation; costs by activity are presented in the
appendix (pp 6, 7). Cost estimation methodologies in first
and subsequent years of scale-up can also be found in the
appendix (pp 5, 6). In year 1 of scale-up, total budgetary
impact costs are estimated to be $103·0 million in
Bangladesh, $57·6 million in Pakistan, and $22·0 million
in Sri Lanka to reach 9·67 million, 5·62 million, and
3·43 million rural individuals with hypertension aged
40 years or older, respectively. Based on national
populations, per-capita costs are estimated to be $0·63 in
Bangladesh, $0·29 in Pakistan, and $1·03 in Sri Lanka
(table 2). Recurring per-participant costs in year 2 of
scale-up are estimated to be $6·52 for Bangladesh, $5·70
for Pakistan, and $6·03 for Sri Lanka, and in year 3 of
scale-up are estimated to be $6·05 for Bagladesh, $5·13
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in Pakistan, and $5·92 in Sri Lanka. From year 1 to year 2
of scale-up, estimated costs (total budget impact) reduced
by 28% in Bangladesh and by 33% in Pakistan, whereas
estimated costs increased by 3% in Sri Lanka; from year 1
to year 3 of scale-up, estimated costs reduced by 24% in
Bangladesh and by 31% in Pakistan, whereas costs
increased by 10% in Sri Lanka. For years 2 and 3,
estimated per-participant and per-capita costs decreased
in Bangladesh and Pakistan mainly because of reduced
training frequencies, as only refresher trainings were
required. For Sri Lanka, although estimated training
costs also decreased, an increase in the cost of medication
subsidies led to a slight increase in total cost.
In our cost-effectiveness analysis, the mean age of
participants in the trial was 57 years in Bangladesh and
Pakistan and 63 years in Sri Lanka.10 Based on
conditional life expectancies, participants are expected
to live an average of 24 additional years in Bangladesh,
22 additional years in Pakistan, and 21 additional
years in Sri Lanka.25 The discounted present value
of future intervention delivery costs for these durations
was added to first-year costs to calculate the mean
incremental cost. The health-care utilisation analysis
(appendix pp 11, 12) reveals an overall increase in mean
number of monthly antihypertensive medications
of 0·11 (95% CI 0·04–0·18) at final follow-up (24 months
after baseline), prompting us to assume that there is
an increased use of antihypertensive medications.
Although we did consider other differences in healthcare costs (appendix pp 11, 12), we found no other
significant differences in costs between treatment and
control groups, and therefore other costs were excluded
from the analysis.
Using a methodical cost estimation of market prices of
antihypertensive medicines in each country (as described
in the appendix [pp 5, 6]), the per-participant lifetime
incremental cost of scaling up COBRA-BPS was estimated
to be $147 in Bangladesh, $136 in Pakistan, and $110 in
Sri Lanka (appendix p 9). Based on the incremental costs
(appendix p 8), the percentage of lifetime costs attributable
to increased use of anti-hypertensive medication is 16%
($221·29 million of $1·42 billion) in Bangladesh, 22%
($165·20 million of $766·33 million) in Pakistan, and
40% ($151·35 million of $377·97 million) in Sri Lanka,
with differences driven by differential medication use
rates and prices across countries.
The primary effectiveness analysis found that systolic
blood pressure in rural communities decreased by a
mean of 4·39 mm Hg (95% CI 7·84–0·94) in Bangladesh,
4·99 mm Hg (9·63–0·35) in Pakistan, and 6·22 mm Hg
(8·98–3·45) in Sri Lanka (table 3). Assuming that every
1 mm Hg reduction in systolic blood pressure translates
into a 2·2% reduction in cardiovascular disease
DALYs,20–22 we multiplied the mean incremental reduction
of systolic blood pressure in each country by 2·2% to
estimate the percentage reduction in cardiovascular
disease DALYs conferred by the COBRA-BPS programme.

Year 1

Year 2

Year 3

Bangladesh (100% coverage)
Cost per participant
Cost per capita*
Eligible population†
Total budget impact*‡

$10·65

$6·52

$0·63

$0·45

$6·05
$0·47

9 671 504

11 391 650

13 009 795

$102 993 340

$74 294 630

$78 652 010

Pakistan (60% coverage)
Cost per participant
Cost per capita*
Eligible population†
Total budget impact‡

$10·25

$5·70

$5·13

$0·29

$0·19

$0·20

5 619 670

6 728 994

7 796 449

$57 610 060

$38 365 390

$40 021 640

Sri Lanka (100% coverage)
Cost per participant

$6·42

$6·03

Cost per capita*

$1·03

$1·05

Eligible population†
Total budget impact‡

$5·92
$1·10

3 428 737

3 763 279

4 079 978

$22 006 890

$22 675 410

$24 140 330

Data are 2020 US$ or n. Costs are rounded to the nearest $0·01 and the total budget impacts are rounded to the
nearest $10. *Cost per capita is total cost divided by total national population count. †Individuals aged 40 years or
older with hypertension in rural communities. ‡A breakdown of the cost types can be found in the appendix (pp 6, 7).

Table 2: Budget impact per participant and per capita from the health ministry perspective, in years 1–3
of implementation

This reduced percentage of cardiovascular disease DALYs
was then multiplied by cardiovascular disease DALYs
borne by the eligible population to estimate the
DALYs savings provided by the COBRA-BPS programme
in each country. Dividing the costs by these savings
yielded base-case incremental cost-effectiveness ratios of
$3430 per DALY averted in Bangladesh, $2270 per DALY
averted in Pakistan, and $4080 per DALY averted in
Sri Lanka (table 3). Based on WHO-CHOICE thresholds
of three times GDP per capita as a guide for what is costeffective,17,26 the base-case estimates (as seen in table 3)
show COBRA-BPS to be cost-effective in all three
countries.
The sensitivity analyses showed that, maintaining
other parameters as constant values, COBRA-BPS would
remain cost-effective at an incremental cost that was
48% higher than the base case in Bangladesh, 97% higher
than the base case in Pakistan, and 202% higher than the
base case in Sri Lanka (appendix p 9). COBRA-BPS would
also remain cost-effective if, all else being equal, mean
incremental reductions of systolic blood pressure were no
lower than 2·96 mm Hg in Bangladesh, 2·54 mm Hg
in Pakistan, and 2·06 mm Hg in Sri Lanka, or if
the percentage improvement in DALYs for each 1 unit
decrease in systolic blood pressure remained above
1·48% in Bangladesh, 1·12% in Pakistan, and 0·73% in
Sri Lanka (appendix p 9). Using a 6% discount rate for
costs instead of the 3% base rate,19 the cost-effectiveness
ratio would improve to $2640 in Bangladesh, $1780 in
Pakistan, and $3210 in Sri Lanka (appendix p 9).
The cost-effectiveness acceptability curves that are
based on the probabilistic sensitivity analyses of
1000 draws23 from the estimated distribution for systolic
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Total incremental cost for cost-effectiveness analysis (US$)*

Bangladesh (100% coverage)

Pakistan (60% coverage)

$1 421 174 180

$766 327 830

Mean incremental reduction of systolic blood pressure (mm Hg)10
Cardiovascular disease DALYs borne by eligible population (n)†
Avertable cardiovascular disease DALYs (n)‡

4·39 (7·84–0·94)

4·99 (9·63–0·35)

Sri Lanka (100% coverage)
$377 973 350
6·22 (8·98–3·45)

4 285 514

3 082 505

676 600
92 586

413 895

338 397

Incremental cost per cardiovascular disease DALY averted (US$)

$3430

$2270

$4080

WHO threshold for being cost-effective (US$)§

$5090

$4450

$12 310

Gross domestic product per capita17

$1560

$1460

$4080

Data are n, mm Hg (95% CI), or 2020 US$. Monetary values are rounded to the nearest $10. DALY=disability-adjusted life-year. *A breakdown of the cost types can be found in the appendix (p 8). †Individuals
aged 40 years or older with hypertension in rural communities. ‡Based on an estimated 2·2% reduction in cardiovascular disease DALYs per 1 mm Hg reduction in systolic blood pressure. §Threshold for being
cost-effective set for at least three times gross domestic product per capita of each country.17,26

Table 3: Cost-effectiveness of COBRA-BPS from the health systems perspective

blood pressure improvements, maintaining all other
values as fixed, are shown in the appendix (pp 9, 10).
These figures present the percentage of iterations that
were predicted to be cost-effective for each willingnessto-pay threshold that decision makers might consider.
Applying the cost-effectiveness guidelines of WHO for
Bangladesh ($5090), Pakistan ($4450), and Sri Lanka
($12 310), COBRA-BPS was predicted to be cost-effective
in 79·3% of iterations in Bangladesh, 85·2% of iterations
in Pakistan, and 99·8% of iterations in Sri Lanka.

Discussion
In the multinational cohort in the PURE study,
which included several low-income and middle-income
countries, hypertension attributed the largest risk to
cardiovascular diseases and death.27 This multi-country,
cluster-randomised trial presents, to our knowledge, the
first evidence that a customisable community-based
intervention led by CHWs can be a cost-effective, scalable,
and potentially sustainable solution for controlling blood
pressure among those with hypertension in rural areas.
Although countries use their own criteria for what is
deemed cost-effective, COBRA-BPS was cost-effective
for each of the three countries according to the WHO
thresholds.
A primary reason for the cost-effectiveness of COBRABPS is the relatively low per-participant cost. Scaling up
COBRA-BPS would cost each country’s government
less than $10·70 per participant in year 1, with
comprehensive training being responsible for roughly
half of the costs. In subsequent years, costs are expected
to decrease as only refresher trainings are required for
existing CHWs. However, if countries need to scale up
the number of CHWs, as might be the case for Sri Lanka
given the low number of CHWs per capita, then training
costs would increase. Sri Lanka is also the only country
where the government pays for medications, and
medication subsidies are responsible for 27% of their
per-participant costs.
When considering per-capita costs across the entire
population of each country, as opposed to per-participant
costs, the costs were estimated at less than $1 per year in
6

Bangladesh and Pakistan, and less than $1·20 per year in
Sri Lanka. Differences in costs across countries result
from differences in the number of CHWs required to be
trained, differences in training costs, and differences in
implementation design, staffing models, wage rates,
and hypertension prevalence, as greater hypertension
prevalence reduces the average fixed cost of the pro
gramme by spreading it across more individuals.
Although previous hypertension trials from lowincome and middle-income countries have also shown
cost-effectiveness based on similar cost-effectiveness
analysis thresholds,28 COBRA-BPS is unique with its
focus on rural populations, integration of all components
into the existing health-care infrastructure, and reliance
on government CHWs to proactively conduct blood
pressure monitoring and health promotion activities.
Leveraging this infrastructure contributed substantially
to the low costs of programme delivery regardless of
differences in programme implementation, hypertension
prevalence, and underlying cost structures. Therefore,
our results are likely to be generalisable to many lowincome and middle-income countries that rely on CHWs.
Given our budget impact projections and current
health budgets of $6·00 per capita in Bangladesh,
$14·00 per capita in Pakistan, and $69·00 per capita in
Sri Lanka,17 the benefits of COBRA-BPS could be achieved
with a health budget increase of 10% in Bangladesh,
3% in Pakistan, and 2% in Sri Lanka in the first year and
slightly less in subsequent years in Bangladesh and
Pakistan (but slightly more in Sri Lanka due to greater
cost of medications). Although affordability is always a
concern, these cost increases are not substantially greater
than other “best buy” interventions recommend by
WHO.29
This study has many strengths, including a standardised
intervention, a rigorous multi-country effectiveness
evaluation, and prospective cost data collection. Yet there
are limitations. One limitation for the cost-effectiveness
analyses is that the cost-effectiveness ratios are based on
an algorithm that directly converts blood pressure reduc
tions to DALYs averted. Although we use conservative
assumptions for this relationship and did sensitivity
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analyses to measure the influence of our assumptions on
results, additional studies should be done to find out
whether this relationship holds over longer time periods.
The analyses also assumed no differences in longterm health-care utilisation across study groups. This
assumption is probably conservative as a successful
intervention should result in fewer cardiovascular disease
events. The analyses also assume that the benefits of
blood pressure reduction and the relationship of blood
pressure reduction with improvement in DALYs would
continue throughout the participants’ lifetime. As some of
the improvements in systolic blood pressure resulted
from overall increased use of medications, both our
cost and cost-effectiveness estimates would be inflated if
usage decreased with time. Consistent with the latest
recommendations, we also did not discount DALYs.24
Discounting DALYs would reduce the cost-effectiveness
ratios to unknown degrees as the timing of future
cardiovascular disease events is unknown. We also did not
measure the effect of COBRA-BPS on the existing duties
of CHWs, which include maternal and child health
services. However, the funds for additional work were
channelled through the district office in each country with
the flexibility to hire additional workers if needed. Thus,
we assume the benefits of COBRA-BPS did not come at
the expense of other programmes. Finally, we limit the
benefits of COBRA-BPS to benefits caused by reductions
in blood pressure. However, our intervention, which also
focuses on nutrition, tobacco cessation, and physical
activity, probably has other benefits that expand beyond
blood pressure improvements.
The programme could be further strengthened by
including other components, such as risk factor reduc
tions for diabetes or other chronic diseases, additional
medication subsidies, or even universal health coverage,
as out-of-pocket costs remain a barrier to access to
medications and health services in Bangladesh, Pakistan,
and Sri Lanka, as well as other countries.2
In summary, this study presents robust evidence for a
cost-effective multicomponent programme led by CHWs,
namely, COBRA-BPS, for the management of hyper
tension in rural communities. The programme’s low cost
and high scalability suggest that it presents a viable
strategy for responding to the growing cardiovascular
disease epidemic in rural communities in low-income
and middle-income countries currently served by CHWs
and should qualify as a priority intervention in the
targeted countries and possibly many other countries.
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